<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.lipidworld.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Lipids in Health and Disease - Most accessed articles</title>
        <link>http://www.lipidworld.com</link>
        <description>The most accessed research articles published by Lipids in Health and Disease</description>
        <dc:date>2012-05-07T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/8/1/7" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/12" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/3/1/25" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/4/1/12" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/11/1/46" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/11/1/42" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/6/1/25" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/11/1/47" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/36" />
                                <rdf:li rdf:resource="http://www.lipidworld.com/content/11/1/44" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.lipidworld.com/content/8/1/7">
        <title>IGOB131, a novel seed extract of the West African plant Irvingia gabonensis, significantly reduces body weight and improves metabolic parameters in overweight humans in a randomized double-blind placebo controlled investigation.</title>
        <description>Background:
A recent in vitro study indicates that IGOB131, a novel seed extract of the traditional West African food plant Irvingia gabonensis, favorably impacts adipogenesis through a variety of critical metabolic pathways including PPAR gamma, leptin, adiponectin, and glycerol-3 phosphate dehydrogenase. This study was therefore aimed at evaluating the effects of IGOB131, an extract of Irvingia gabonensis, on body weight and associated metabolic parameters in overweight human volunteers.
Methods:
The study participants comprised of 102 healthy, overweight and/or obese volunteers (defined as BMI &gt; 25 kg/m2) randomly divided into two groups. The groups received on a daily basis, either 150 mg of IGOB131 or matching placebo in a double blinded fashion, 30&#8211;60 minutes before lunch and dinner. At baseline, 4, 8 and 10 weeks of the study, subjects were evaluated for changes in anthropometrics and metabolic parameters to include fasting lipids, blood glucose, C-reactive protein, adiponectin, and leptin.
Results:
Significant improvements in body weight, body fat, and waist circumference as well as plasma total cholesterol, LDL cholesterol, blood glucose, C-reactive protein, adiponectin and leptin levels were observed in the IGOB131 group compared with the placebo group.
Conclusion:
Irvingia gabonensis administered 150 mg twice daily before meals to overweight and/or obese human volunteers favorably impacts body weight and a variety of parameters characteristic of the metabolic syndrome. This is the first double blind randomized placebo controlled clinical trial regarding the anti-obesity and lipid profile modulating effects of an Irvingia gabonensis extract. The positive clinical results, together with our previously published mechanisms of gene expression modulation related to key metabolic pathways in lipid metabolism, provide impetus for much larger clinical studies. Irvingia gabonensis extract may prove to be a useful tool in dealing with the emerging global epidemics of obesity, hyperlipidemia, insulin resistance, and their co-morbid conditions.Trial registrationClinicalTrials.gov NCT00645775</description>
        <link>http://www.lipidworld.com/content/8/1/7</link>
                <dc:creator>Judith Ngondi</dc:creator>
                <dc:creator>Blanche Etoundi</dc:creator>
                <dc:creator>Christine Nyangono</dc:creator>
                <dc:creator>Carl Mbofung</dc:creator>
                <dc:creator>Julius Oben</dc:creator>
                <dc:source>Lipids in Health and Disease 2009, null:7</dc:source>
        <dc:date>2009-03-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-8-7</dc:identifier>
                                <prism:require>/content/figures/1476-511X-8-7-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2009-03-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/7/1/12">
        <title>The use of a Cissus quadrangularis/Irvingia gabonensis combination in the management of weight loss: a double-blind placebo-controlled study</title>
        <description>AimTo evaluate the effects of two formulations, Cissus quadrangularis-only and a Cissus quadrangularis/Irvingia gabonensis combination, on weight loss in overweight and obese human subjects.
Methods:
The study was a 10 week randomized, double-blind, placebo-controlled design involving 72 obese or overweight participants (45.8% male; 54.2% female; ages 21&#8211;44; mean age = 29.3). The participants were randomly divided into three equal (n = 24) groups: placebo, Cissus quadrangularis-only, and Cissus quadrangularis/Irvingia gabonensis combination. Capsules containing the placebo or active formulations were administered twice daily before meals; no major dietary changes nor exercises were suggested during the study. A total of six anthropomorphic and serological measurements (body weight, body fat, waist size; total plasma cholesterol, LDL cholesterol, fasting blood glucose level) were taken at baseline and at 4, 8 and 10 weeks.
Results:
Compared to the placebo group, the two active groups showed a statistically significant difference on all six variables by week 10. The magnitude of the differences was noticeable by week 4 and continued to increase over the trial period.
Conclusion:
Although the Cissus quadrangularis-only group showed significant reductions on all variables compared to the placebo group, the Cissus quadrangularis/Irvingia gabonensis combination resulted in even larger reductions. This apparently synergistic formulation should prove helpful in the management of obesity and its related complications.</description>
        <link>http://www.lipidworld.com/content/7/1/12</link>
                <dc:creator>Julius Oben</dc:creator>
                <dc:creator>Judith Ngondi</dc:creator>
                <dc:creator>Claudia Momo</dc:creator>
                <dc:creator>Gabriel Agbor</dc:creator>
                <dc:creator>Caroline Makamto Sobgui</dc:creator>
                <dc:source>Lipids in Health and Disease 2008, null:12</dc:source>
        <dc:date>2008-03-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-7-12</dc:identifier>
                                <prism:require>/content/figures/1476-511X-7-12-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2008-03-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/3/1/25">
        <title>Omega-3 fatty acids and major depression: A primer for the mental health professional</title>
        <description>Omega-3 fatty acids play a critical role in the development and function of the central nervous system. Emerging research is establishing an association between omega-3 fatty acids (alpha-linolenic, eicosapentaenoic, docosahexaenoic) and major depressive disorder. Evidence from epidemiological, laboratory and clinical studies suggest that dietary lipids and other associated nutritional factors may influence vulnerability and outcome in depressive disorders. Research in this area is growing at a rapid pace. The goal of this report is to integrate various branches of research in order to update mental health professionals.</description>
        <link>http://www.lipidworld.com/content/3/1/25</link>
                <dc:creator>Alan Logan</dc:creator>
                <dc:source>Lipids in Health and Disease 2004, null:25</dc:source>
        <dc:date>2004-11-09T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-3-25</dc:identifier>
                                <prism:require>/content/figures/1476-511X-3-25-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>25</prism:startingPage>
        <prism:publicationDate>2004-11-09T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/4/1/12">
        <title>The effect of Irvingia gabonensisseeds on body weight and blood lipids of obese subjects in Cameroon</title>
        <description>Dietary fibres are frequently used for the treatment of obesity. The aim of this study was to evaluate the efficacy of Irvingia gabonensis seeds in the management of obesity. This was carried out as a double blind randomised study involving 40 subjects (mean age 42.4 years). Twenty-eight subjects received Irvingia gabonensis (IG) (1.05 g three time a day for one month) while 12 were on placebo (P) and the same schedule. During the one-month study period all subjects were on a normocaloric diet evaluated every week by a dietetic record book. At the end, the mean body weight of the IG group was decreased by 5.26 &#177; 2.37% (p &lt; 0.0001) and that of the placebo group by 1.32 &#177; 0.41% (p &lt; 0.02). The difference observed between the IG and the placebo groups was significant (p &lt; 0.01). The obese patients under Irvingia gabonensis treatment also had a significant decrease of total cholesterol, LDL-cholesterol, triglycerides, and an increase of HDL-cholesterol. On the other hand, the placebo group did not manifest any changes in blood lipid components. Irvingia gabonensis seed may find application in weight lose.</description>
        <link>http://www.lipidworld.com/content/4/1/12</link>
                <dc:creator>Judith Ngondi</dc:creator>
                <dc:creator>Julius Oben</dc:creator>
                <dc:creator>Samuel Minka</dc:creator>
                <dc:source>Lipids in Health and Disease 2005, null:12</dc:source>
        <dc:date>2005-05-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-4-12</dc:identifier>
                                <prism:require>/content/figures/1476-511X-4-12-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2005-05-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/11/1/46">
        <title>Association of ATP binding cassette transporter G8 rs4148217 SNP and serum lipid levels in Mulao and Han nationalities</title>
        <description>Background:
The association of ATP binding cassette transporter G8 gene (ABCG8) rs4148217 single nucleotide polymorphism (SNP) and serum lipid profiles is still controversial in diverse racial/ethnic groups. Mulao nationality is an isolated minority in China. The aim of this study was to evaluate the association of ABCG8 rs4148217 SNP and several environmental factors with serum lipid levels in the Guangxi Mulao and Han populations.
Methods:
A total of 634 subjects of Mulao nationality and 717 participants of Han nationality were randomly selected from our previous samples. Genotyping of the ABCG8 rs4148217 SNP was performed by polymerase chain reaction and restriction fragment length polymorphism combined with gel electrophoresis, and then confirmed by direct sequencing.
Results:
The genotypic and allelic frequencies of ABCG8 rs4148217 SNP were different between the two nationalities (P &lt; 0.01 for each), the frequency of A allele was higher in Mulao than in Han. The A allele carriers in Han had lower high-density lipoprotein cholesterol (HDL-C) and apolipoprotein (Apo) A1 levels than the A allele noncarriers (P &lt; 0.05 for each), whereas the A allele carriers in Mulao had lower ApoA1 levels than the A allele noncarriers (P &lt; 0.05). Subgroup analyses showed that the A allele carriers in Han had lower HDL-C and higher triglyceride (TG) levels in females but not in males than the A allele noncarriers (P &lt; 0.05 for each), and the A allele carriers in Mulao had lower ApoA1 levels in females but not in males than the A allele noncarriers (P &lt; 0.05). The levels of TG and HDL-C in Han, and ApoA1 in Mulao were associated with genotypes in females but not in males (P &lt; 0.05-0.01). Serum lipid parameters were also correlated with several environmental factors (P &lt; 0.05-0.001).
Conclusions:
The ABCG8 rs4148217 SNP is associated with serum TG, HDL-C and ApoA1 levels in our study populations, but this association is different between the Mulao and Han populations. There is a sex (female)-specific association in both ethnic groups.</description>
        <link>http://www.lipidworld.com/content/11/1/46</link>
                <dc:creator>Qing Li</dc:creator>
                <dc:creator>Xian-Liang Wei</dc:creator>
                <dc:creator>Rui-Xing Yin</dc:creator>
                <dc:source>Lipids in Health and Disease 2012, null:46</dc:source>
        <dc:date>2012-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-11-46</dc:identifier>
                                <prism:require>/content/figures/1476-511X-11-46-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>46</prism:startingPage>
        <prism:publicationDate>2012-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/11/1/42">
        <title>Influence of vitamin D supplementation on plasma lipid profiles: A meta-analysis of randomized controlled trials</title>
        <description>Observational studies have shown that low serum levels of vitamin D have been associated with an atherogenic lipid profile. However, the intervention studies gave divergent results. We conducted a meta-analysis of randomized controlled trials that evaluated the effects of vitamin D supplementation on blood lipids. A systematic literature search was conducted via MEDLINE, Cochrane library, and EMBASE for randomized controlled clinical trials assessing the effects of vitamin D supplementation on lipids. The mean change in total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) from baseline was treated as a continuous variable. In all, 12 clinical trials consisting of 1346 participants were included in the analysis. The pooled estimate of effect for vitamin D supplementation on LDL-C was 3.23 mg/dl (95% confidence interval, 0.55 to 5.90 mg/dl). No statistically significant effects for vitamin D supplementation were observed for TC, HDL-C and TG (differences in means were 1.52 mg/dl (-1.42 to 4.46 mg/dl), -0.14 mg/dl (-0.99 to 0.71 mg/dl) and -1.92 mg/dl (-7.72 to 3.88 mg/dl) respectively). The lipid modulating effects of vitamin D supplementation should be further investigated though large-scale, randomized trials with adequate doses which can effectively elevated the active form of vitamin D in plasma and with proper population which has hyperlipemia as an inclusion criterion.</description>
        <link>http://www.lipidworld.com/content/11/1/42</link>
                <dc:creator>Hao Wang</dc:creator>
                <dc:creator>Ning Xia</dc:creator>
                <dc:creator>Yang Yang</dc:creator>
                <dc:creator>Dao-Quan Peng</dc:creator>
                <dc:source>Lipids in Health and Disease 2012, null:42</dc:source>
        <dc:date>2012-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-11-42</dc:identifier>
                                <prism:require>/content/figures/1476-511X-11-42-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>42</prism:startingPage>
        <prism:publicationDate>2012-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/6/1/25">
        <title>Bovine milk in human nutrition - a review.</title>
        <description>Milk and milk products are nutritious food items containing numerous essential nutrients, but in the western societies the consumption of milk has decreased partly due to claimed negative health effects. The content of oleic acid, conjugated linoleic acid, omega-3 fatty acids, short- and medium chain fatty acids, vitamins, minerals and bioactive compounds may promote positive health effects. Full-fat milk has been shown to increase the mean gastric emptying time compared to half-skimmed milk, thereby increasing the gastrointestinal transit time. Also the low pH in fermented milk may delay the gastric emptying. Hence, it may be suggested that ingesting full-fat milk or fermented milk might be favourable for glycaemic (and appetite?) regulation. For some persons milk proteins, fat and milk sugar may be of health concern. The interaction between carbohydrates (both natural milk sugar and added sugar) and protein in milk exposed to heat may give products, whose effects on health should be further studied, and the increasing use of sweetened milk products should be questioned. The concentration in milk of several nutrients can be manipulated through feeding regimes. There is no evidence that moderate intake of milk fat gives increased risk of diseases.</description>
        <link>http://www.lipidworld.com/content/6/1/25</link>
                <dc:creator>Anna Haug</dc:creator>
                <dc:creator>Arne Hostmark</dc:creator>
                <dc:creator>Odd Harstad</dc:creator>
                <dc:source>Lipids in Health and Disease 2007, null:25</dc:source>
        <dc:date>2007-09-25T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-6-25</dc:identifier>
                                <prism:require>/content/figures/1476-511X-6-25-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>25</prism:startingPage>
        <prism:publicationDate>2007-09-25T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/11/1/47">
        <title>Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status</title>
        <description>Dyslipidemia is common in chronic hemodialysis patients and its underlying mechanism is complex. Hemodialysis causes an imbalance between antioxidants and production of reactive oxygen species, which induces the oxidative stress and thereby may lead to accelerated atherosclerosis. Statins have been found to be little effective in end-stage kidney disease and other lipid-lowering therapies have been only scarcely studied. The study aimed to assess the effect of low-dose fenofibrate therapy on plasma lipids and redox status in long-term hemodialysis patients with mild hypertriglyceridemia.Twenty seven chronic hemodialysis patients without any lipid-lowering therapy were included in a double-blind crossover, placebo-controlled study. The patients were randomized into two groups and were given a sequence of either 100 mg of fenofibrate per each hemodialysis day for 4 weeks or placebo with a week-long wash-out period between treatment periods. Plasma lipids, high sensitive C-reactive protein (CRP), urea, creatinine, electrolytes, phosphocreatine kinase (CK), GOT, GPT and plasma thiols (total and free glutathione, homocysteine, cysteine and cysteinylglycine) were measured at baseline and after each of the study periods. Plasma aminothiols were measured by reversed phase HPLC with thiol derivatization with 2-chloro-1-methylquinolinium tetrafluoroborate.Fenofibrate therapy caused a significant decrease of total serum cholesterol, LDL cholesterol and triglycerides and an increase of HDL cholesterol. The treatment was well tolerated with no side-effects but there was a small but significant increase of CK not exceeding the upper limit of normal range. There were no changes of serum CRP, potassium, urea, and creatinine and liver enzymes during the treatment. Neither total nor total free cysteinylglycine and cysteine changed during the study but both total and free glutathione increased during the therapy with fenofibrate and the same was observed in case of plasma homocysteine.The study shows that a treatment with reduced fenofibrate dose is safe and effective in reducing serum triglycerides and cholesterol in chronic dialysis patients and may shift plasma aminothiol balance towards a more antioxidative pattern.</description>
        <link>http://www.lipidworld.com/content/11/1/47</link>
                <dc:creator>Agnieszka Makowka</dc:creator>
                <dc:creator>Przemyslaw Dryja</dc:creator>
                <dc:creator>Grazyna Chwatko</dc:creator>
                <dc:creator>Edward Bald</dc:creator>
                <dc:creator>Michal Nowicki</dc:creator>
                <dc:source>Lipids in Health and Disease 2012, null:47</dc:source>
        <dc:date>2012-05-07T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-11-47</dc:identifier>
                                <prism:require>/content/figures/1476-511X-11-47-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>47</prism:startingPage>
        <prism:publicationDate>2012-05-07T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/7/1/36">
        <title>Acne vulgaris, mental health and omega-3 fatty acids: a report of cases

</title>
        <description>Acne vulgaris is a common skin condition, one that is associated with significant psychological disability. The psychological impairments in acne include higher rates of depression, anxiety, anger and suicidal thoughts. Despite a paucity of clinical research, patients with skin conditions and/or mental health disorders are frequent consumers of dietary supplements. An overlap may exist between nutrients that potentially have both anti-acne and mood regulating properties; examples include omega-3 fatty acids from fish oil, chromium, zinc and selenium. Here we report on five cases of acne treated with eicosapentaenoic acid and antioxidant nutrients. Self-administration of these nutrients may have improved inflammatory acne lesions and global aspects of well-being; the observations suggest a need for controlled trials.</description>
        <link>http://www.lipidworld.com/content/7/1/36</link>
                <dc:creator>Mark Rubin</dc:creator>
                <dc:creator>Katherine Kim</dc:creator>
                <dc:creator>Alan Logan</dc:creator>
                <dc:source>Lipids in Health and Disease 2008, null:36</dc:source>
        <dc:date>2008-10-13T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-7-36</dc:identifier>
                            <dc:title>Food for your face</dc:title>
                            <dc:description>Acne vulgaris and the associated psychological effects could be treated through a diet rich in omega-3 fatty acids, chromium, zinc and selenium.</dc:description>
                <prism:require>/content/figures/1476-511X-7-36-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>36</prism:startingPage>
        <prism:publicationDate>2008-10-13T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.lipidworld.com/content/11/1/44">
        <title>A high normal TSH level is associated with an atherogenic lipid profile in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease</title>
        <description>Background:
Serum lipid profiles may be influenced by thyroid function, but the detailed mechanism remains unclear. Increasing evidence suggests that thyrotropin (TSH) may exert extra-thyroidal effects. The goal of this study was to evaluate the relationship between serum TSH levels and the lipid profiles in euthyroid non-smokers with newly diagnosed asymptomatic coronary heart disease (CHD).
Methods:
This was a retrospective study of 406 euthyroid non-smokers (187 males and 219 females) with newly diagnosed asymptomatic CHD from 2004 to 2010 in Jinan, China. Lipid parameters and the levels of TSH, FT3, and FT4 were determined. Multiple linear regression analysis and Logistic regression analysis were used to assess the influence of TSH on the lipid profiles and the risks of dyslipidemia.
Results:
The TSH level, even within the normal range, was positively and linearly correlated with total cholesterol (TC), non-high density lipoprotein cholesterol (non-HDL-C) and triglycerides (TG) (Beta = 0.173, 0.181 and 0.103, respectively, P &lt; 0.01 in all). With 1 mIU/L rise of TSH, the levels of TC, TG and non-HDL-C will increase by 1.010, 1.064, and 1.062 mmol/L, respectively. The odds ratio of hypercholesterolemia and hypertriglyceridemia with respect to the serum TSH level was 1.640 (95% CI 1.199-2.243, P = 0.002) and 1.349 (95% CI 1.054-1.726, P = 0.017), respectively.
Conclusions:
TSH levels were correlated in a positive linear manner with the TC, non-HDL-C and TG levels in euthyroid non-smokers with newly diagnosed asymptomatic CHD. TSH in the upper limits of the reference range might exert adverse effects on lipid profiles and thus representing as a risk factor for hypercholesterolemia and hypertriglyceridemia in the context of CHD.</description>
        <link>http://www.lipidworld.com/content/11/1/44</link>
                <dc:creator>Xing Wanjia</dc:creator>
                <dc:creator>Wang Chenggang</dc:creator>
                <dc:creator>Wang Aihong</dc:creator>
                <dc:creator>Yang Xiaomei</dc:creator>
                <dc:creator>Zhao Jiajun</dc:creator>
                <dc:creator>Yu Chunxiao</dc:creator>
                <dc:creator>Xu Jin</dc:creator>
                <dc:creator>Hou Yinglong</dc:creator>
                <dc:creator>Gao Ling</dc:creator>
                <dc:source>Lipids in Health and Disease 2012, null:44</dc:source>
        <dc:date>2012-03-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-511X-11-44</dc:identifier>
                                <prism:require>/content/figures/1476-511X-11-44-toc.gif</prism:require>
                <prism:publicationName>Lipids in Health and Disease</prism:publicationName>
        <prism:issn>1476-511X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>44</prism:startingPage>
        <prism:publicationDate>2012-03-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

